1. Introduction {#sec1}
===============

Sepsis from*Pseudomonas aeruginosa* bacteremia may be fatal and necessitates prompt antimicrobial therapy. Newer antimicrobials have been developed to address the rise of multidrug-resistant*P. aeruginosa* \[[@B1]\]. Among these are ceftolozane-tazobactam, a combination of a fifth-generation cephalosporin and a *β*-lactamase inhibitor, and ceftazidime-avibactam, a combination of a third-generation cephalosporin and a non-*β*-lactam *β*-lactamase inhibitor \[[@B2]\]. We present the first case report of persistent*P. aeruginosa* bacteremia resistant to these novel antibiotics.

2. Case Presentation {#sec2}
====================

A 68-year-old man presents to the Emergency Department for a 6-month history of worsening fatigue, anorexia, and weight loss. CT scan of the abdomen showed enlarged lymph nodes. Axillary lymph node biopsy showed follicular lymphoma with bone marrow involvement. The patient was started on chemotherapy with rituximab, etoposide, prednisolone, oncovin, cyclophosphamide, and hydroxyl-daunorubicin (R-EPOCH). Second cycle consisted of rituximab, cyclophosphamide, hydroxyl-daunorubicin, oncovin, and prednisone (R-CHOP). The patient had a prolonged hospital course (3 months) complicated by tumor lysis syndrome, febrile neutropenia (treated with aztreonam, cefepime, and anidulafungin), acute renal failure requiring hemodialysis, right lower extremity cellulitis treated with a 7-day course of intravenous vancomycin, and*Clostridium difficile* colitis treated with oral metronidazole.

On hospital discharge, outpatient chemotherapy consisted of bendamustine and rituximab. Two weeks later, the patient presented to the clinic for recurrence of right lower extremity cellulitis. Physical exam revealed erythema and induration of the right upper leg with extension to the groin and left medial thigh. One dose of intravenous ceftriaxone was administered and amoxicillin-clavulanate 500 mg three times a day was started. The patient presented 1 day later to the Emergency Department with increased shortness of breath, loose bowel movement, hypotension (80/40), tachycardia (129 beats/minute), temperature of 99.6°F, and oxygen saturation of 75% in room air. Empiric vancomycin and piperacillin-tazobactam were started and 6 liters of normal saline bolus led to improvement in blood pressure. Hospital course is summarized in [Table 1](#tab1){ref-type="table"}.

Blood cultures from the day of admission grew*P. aeruginosa* ([Table 2](#tab2){ref-type="table"}), identified using VITEK 2 (Biomerieux, Lenexa, KS). Blood cultures persistently grew*P. aeruginosa* initially susceptible to piperacillin-tazobactam and cefepime, with subsequent resistance to all cephalosporins and penicillins by Day 5 and resistance to meropenem by Day 10. Antimicrobial susceptibility testing to ceftolozane-tazobactam and ceftazidime-avibactam was performed for the*P. aeruginosa* isolate from Day 10 by measuring minimum inhibitory concentration using *E*-test (Biomerieux, Lenexa, KS). *E*-test showed 0 mm zone of inhibition for ceftazidime-avibactam (resistant) and 16 mm for ceftolozane-tazobactam (resistant).

The patient had an extensive work-up to find the source of*P. aeruginosa* bacteremia. Transesophageal echocardiogram did not show vegetation or endocarditis. Noncontrast CT scan of the chest, abdomen, and pelvis revealed bilateral pleural effusions but no abscess. Low platelet counts precluded thoracentesis. Urine cultures (Day 1, Day 10, and Day 15), as well as catheter tip culture of peripherally inserted central catheter line (PICC line), did not grow bacteria.

Antimicrobial coverage was adjusted appropriately based on blood culture susceptibility reports. Despite medical treatment, the patient developed progressive acidosis, respiratory distress, and hypotension. By Day 15, he required three vasopressors. A decision was made to shift the patient from full interventions to comfort measures only. He was extubated and expired on Day 16 of hospitalization.

To determine possible underlying resistance mechanisms in the*P. aeruginosa* isolate, the Verigene Blood Culture-Gram-Negative (BC-GN) microarray-based assay (Nanosphere, Inc., Northbrook, IL) was utilized following previously published methods \[[@B3]\]. In brief, we seeded a known negative blood culture bottle with the*P. aeruginosa* isolate using 100 mL of a 0.5 McFarland standard in normal saline. Blood culture bottles were placed on the BACTEC automated blood culture monitoring system (BD Diagnostics, Franklin Lakes, NJ, USA). Once they were flagged positive, we took four 1 mL aliquots and placed them in sterile tubes. The tubes were immediately placed in −70°F freezer before shipping on dry ice to Nanosphere, Inc. (Illinois, USA). The Verigene BC-GN detected*P. aeruginosa*. However, all resistance markers tested were negative (CTX-M, KPC, NDM, VIM, IMP, or OXA gene).

3. Discussion {#sec3}
=============

We present the first documented case of persistent*P. aeruginosa* bacteremia resistant to the novel antimicrobials ceftazidime-avibactam and ceftolozane-tazobactam. A recent publication on a multidrug-resistant*P. aeruginosa* bacteremia was reported by Bremmer and colleagues, but the isolate was susceptible to ceftolozane-tazobactam \[[@B4]\]. In our current report, a rapid development of antibiotic resistance was observed despite appropriate antimicrobial therapy and, intriguingly, with resistance to ceftazidime-avibactam and ceftolozane-tazobactam, agents that have been only recently approved by the US Food and Drug Administration. This case raises the following important questions: (1) Must patients remain on double antimicrobial coverage for*P. aeruginosa* pending*repeat* blood cultures? (2) Should screening for resistance determinants be routinely performed for*P. aeruginosa*?

The rationale for double antibiotic coverage/combination therapy against suspected*P. aeruginosa* infection is to increase the chance that the patient receives an active agent awaiting final susceptibility results. Combination therapy also has a theoretical benefit in decreasing the emergence of resistance and may confer synergistic effect. Although the routine use of combination antimicrobials for*P. aeruginosa* remains controversial, there is evidence that a subset of patients who are at high risk for resistant strains (i.e., patients with neutropenia, burn, severe sepsis, or shock) may benefit from combination therapy \[[@B5]\]. Measuring peak and minimum inhibitory concentrations for ciprofloxacin and aminoglycosides was also shown to be associated with increased success/clinical cure in*P. aeruginosa* bacteremia \[[@B6]\].

In our current report, despite appropriate antimicrobial therapy and initial isolate susceptible to piperacillin-tazobactam, the patient continued to have bacteremia. There are two possible reasons for this: (1) the patient has multiple*P. aeruginosa* strains and the predominant phenotype from Day 1 was eradicated by piperacillin-tazobactam, with the carbapenem-resistant strains subsequently becoming the predominant phenotype in the repeat blood cultures or (2) the initial*P. aeruginosa* isolate developed resistance from mutation/acquisition of exogenous resistance determinants.

The ability of*P. aeruginosa* to develop resistance during antimicrobial therapy has been well-documented in literature and involves complex mechanisms, including chromosomally encoded AmpC cephalosporinase, outer membrane porin (OprD), and multidrug efflux pumps \[[@B7]\]. AmpC *β*-lactamases are chromosomally encoded cephalosporinases. AmpC enzymes may be induced and expressed at high levels by mutation. Overexpression of AmpC confers resistance to broad-spectrum cephalosporins, including ceftazidime \[[@B8]\]. Furthermore, structural modifications in AmpC may impact the ability of avibactam to protect ceftazidime from hydrolysis \[[@B9]\]. A study comparing wild-type and mutator*P. aeruginosa* strains showed that the development of high-level resistance to ceftolozane-tazobactam occurs in the presence of*P. aeruginosa* mutator strains and that multiple mutations result in overexpression and structural modifications of AmpC \[[@B10]\]. Resistance to carbapenems, on the other hand, can arise from a simple mutation in*P. aeruginosa* and one mechanism is through the loss of OprD, a carbapenem-specific porin \[[@B11]\].

We initially thought that the*P. aeruginosa* isolate from our current patient produces metallo-*β*-lactamase, which confers resistance to both cephalosporins and carbapenems \[[@B12]\]. However, it was surprising that the Verigene BC-GN did not detect any of the carbapenemases tested (KPC, NDM, VIM, IMP, or OXA gene). The resistance that we observed may be due to a mechanism not in the BC-GN panel, or the*P. aeruginosa* strain may have acquired resistance through other novel mechanisms. Unfortunately, our limited resources precluded us from testing the isolate for possible chromosomal resistance mechanisms at a reference laboratory.

Another limitation of our case report is the lack of testing of the initial isolate\'s susceptibility to ceftolozane-tazobactam and ceftazidime-avibactam from Day 1. Per our Microbiology lab protocol, positive blood culture samples are discarded 1 week after the Microbiology report has been finalized. When the patient\'s blood culture sample from Day 10 showed resistance to meropenem and the decision was made to test for ceftolozane-tazobactam and ceftazidime-avibactam, blood sample from Day 1 was no longer available. Hence, susceptibility testing was performed only on the most recent blood culture (Day 10).

Unlike the presence of extended-spectrum *β*-lactamase production in*Enterobacteriaceae*, the presence of resistance determinants in*P. aeruginosa* is not routinely tested in most hospitals. Whether testing for carbapenemases and other resistance determinants prior to initiation of antimicrobial treatment would impact mortality among patients with*P. aeruginosa* bacteremia remains to be elucidated. Continued antimicrobial susceptibility surveillance, development of cost-effective screening tests for antimicrobial resistance, and further studies on appropriate treatment strategies in persistent*P. aeruginosa* bacteremia are warranted.
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###### 

Significant events in the patient\'s hospital course.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Hospital day                   Significant event                                                                                                                                                                                         *T*max (°F)   WBC (cells/mm^3^)   Antibiotics
  ------------------------------ --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------- ------------------- --------------------------------------------------
  1                              Admission to the medical ICU, being started on norepinephrine for hypotension\                                                                                                                            103.0         4.61                Piperacillin-tazobactam 4.5 g IV every 8 hours\
                                 Blood cultures drawn\                                                                                                                                                                                                                       Vancomycin IV^*∗*^
                                 Right radial A-line and left femoral central line inserted                                                                                                                                                                                  

  2                              Noncontrast CT scan of abdomen and pelvis showed bilateral pleural effusion, moderate ascites, generalized anasarca, no abscess                                                                           100.7         11.16               

  3                              Day 1 blood cultures grew\                                                                                                                                                                                99.8          15.60               Cefepime 2 gm IV daily
                                 *P. aeruginosa* \                                                                                                                                                                                                                           
                                 Stool *C. difficile* enzyme immune-assay positive^*∗∗*^                                                                                                                                                                                     

  4                              Rising creatinine (1.8 mg/dL)\                                                                                                                                                                            98.3          17.07               
                                 Urinary catheter removed\                                                                                                                                                                                                                   
                                 Femoral line removed\                                                                                                                                                                                                                       
                                 PICC line inserted                                                                                                                                                                                                                          

  5                              Hemoglobin decreased from 7.2 to 6.8 g/dL\                                                                                                                                                                97.7          14.29               
                                 Platelets decreased from 27 to 16 × 10^3^/microliter\                                                                                                                                                                                       
                                 1 unit of packed RBC transfused\                                                                                                                                                                                                            
                                 Repeat blood cultures drawn                                                                                                                                                                                                                 

  6                              Blood pressure stable off vasopressor, arterial line removed\                                                                                                                                             97.8          6.38                
                                 Repeat blood culture negative to date\                                                                                                                                                                                                      
                                 Transferred to general medical floor                                                                                                                                                                                                        

  7                              Repeat blood culture × 1, no growth\                                                                                                                                                                      97.8          12.4                
                                 Minimal bleeding from nares, platelets transfused                                                                                                                                                                                           

  8                              Blood culture from Day 5 resistant to cefepime                                                                                                                                                            98.2          11.93               Meropenem 1 g IV every 8 hours

  9                              1 unit of packed RBC transfused                                                                                                                                                                           99.0          9.68                

  10                             Transthoracic 2D ECHO showed possible valvular vegetations\                                                                                                                                               98.4          5.96                Meropenem 1 g IV every 8 hours + tobramycin^*∗*^
                                 HIDA scan, negative\                                                                                                                                                                                                                        
                                 Intubated for decreased respiratory rate and apnea, hypotension (75/50), altered mental status\                                                                                                                                             
                                 Repeat blood cultures were drawn\                                                                                                                                                                                                           
                                 Transferred back to the medical ICU                                                                                                                                                                                                         

  11                             Hypotension despite fluid resuscitation\                                                                                                                                                                  98.0          6.29                
                                 Phenylephrine started                                                                                                                                                                                                                       

  12                             Transesophageal echocardiogram did not reveal vegetations\                                                                                                                                                98.3          4.35                
                                 PICC line removed and sent for culture\                                                                                                                                                                                                     
                                 Stable respiratory status; patient extubated                                                                                                                                                                                                

  13                             Worsening renal function and oliguria\                                                                                                                                                                    99.3          3.84                Tobramycin 1.7 mg/kg every 12 hours
                                 Blood culture from Day 10 grew *P. aeruginosa* resistant to meropenem; *E*-test performed for *P. aeruginosa* isolate from Day 10 showed resistance to ceftazidime-avibactam and ceftolozane-tazobactam                                     

  14                             Increasing tachypnea, tachycardia, lethargy                                                                                                                                                               98.5          1.54                

  15                             Absolute neutrophil count dropped to 590 cells/mm^3^ \                                                                                                                                                    98.5          2.53                Tobramycin 1.7 mg/kg every 12 hours\
                                 Reintubated for respiratory distress\                                                                                                                                                                                                       Anidulafungin 200 mg IV\
                                 Hypotension despite fluids; patient on three vasopressors (norepinephrine, phenylephrine, vasopressin)\                                                                                                                                     Cefepime 2 gm IV daily\
                                 Repeat blood cultures drawn                                                                                                                                                                                                                 Vancomycin IV

  16                             Family decided to change the patient\'s code status from full interventions to comfort measures only                                                                                                                                         

  He was extubated and expired                                                                                                                                                                                                                                               
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^*∗*^Tobramycin and vancomycin doses were adjusted by pharmacy based on peak and trough blood levels.

^*∗∗*^Patient was on oral vancomycin empirically for *C. difficile*since Day 1 of hospitalization.

HIDA scan: hepatobiliary iminodiacetic acid scan; IV, intravenous; PICC: peripherally-inserted central catheter; and *T*max, maximum temperature.

###### 

Antimicrobial susceptibility of *Pseudomonas aeruginosa* isolated from the blood.

  Antimicrobial             Day 1   Day 5   Day 10^*∗*^   Day 15                     
  ------------------------- ------- ------- ------------- -------- ------ --- ------ ---
  Piperacillin-tazobactam   32      S       ≥128          R        ≥128   R   ≥128   R
  Cefepime                  8       S       32            R        ≥64    R   ≥64    R
  Aztreonam                 16      I       16            I        ≥64    R   ≥64    R
  Meropenem                 4       S       4             S        ≥16    R   ≥16    R
  Amikacin                  16      S       16            S        16     S   16     S
  Gentamicin                8       I       8             I        ≥16    R   ≥16    R
  Tobramycin                ≤1      S       ≤1            S        ≤1     S   ≤1     S
  Ciprofloxacin             ≥4      R       ≤4            R        ≥4     R   ≥4     R
  Tigecycline               ≥8      R       ≤8            R        ≥8     R   ≥8     R

Int, interpretation; MIC, minimum inhibitory concentration; R, resistant; S, susceptible; and I, intermediate.

^*∗*^Antimicrobial susceptibility testing of *P. aeruginosa* against ceftolozane-tazobactam (C/T) and ceftazidime-avibactam (CZA) by *E*-test was performed for the *Pseudomonas* isolate from Day 10. *E*-test showed 0 mm zone of inhibition for CZA (resistant) and 16 mm for C/T (resistant). Cefepime was used as a surrogate for ceftazidime susceptibility.
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